Renalytix Past Earnings Performance
Past criteria checks 0/6
Renalytix's earnings have been declining at an average annual rate of -25.3%, while the Healthcare Services industry saw earnings growing at 6.8% annually. Revenues have been growing at an average rate of 36.6% per year.
Key information
-25.3%
Earnings growth rate
-19.1%
EPS growth rate
| Healthcare Services Industry Growth | 7.9% |
| Revenue growth rate | 36.6% |
| Return on equity | n/a |
| Net Margin | -1,191.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Renalytix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -28 | 17 | 7 |
| 30 Jun 24 | 2 | -33 | 20 | 9 |
| 31 Mar 24 | 2 | -37 | 22 | 11 |
| 31 Dec 23 | 2 | -42 | 25 | 13 |
| 30 Sep 23 | 3 | -44 | 26 | 13 |
| 30 Jun 23 | 3 | -46 | 29 | 14 |
| 31 Mar 23 | 4 | -40 | 33 | 14 |
| 31 Dec 22 | 4 | -42 | 36 | 14 |
| 30 Sep 22 | 3 | -47 | 40 | 14 |
| 30 Jun 22 | 3 | -45 | 40 | 15 |
| 31 Mar 22 | 3 | -50 | 36 | 15 |
| 31 Dec 21 | 2 | -44 | 31 | 14 |
| 30 Sep 21 | 2 | -38 | 27 | 12 |
| 30 Jun 21 | 1 | -35 | 23 | 10 |
| 31 Mar 21 | 1 | -28 | 18 | 8 |
| 31 Dec 20 | 0 | -20 | 11 | 9 |
| 30 Sep 20 | 0 | -16 | 9 | 5 |
| 30 Jun 20 | 0 | -10 | 6 | 5 |
| 31 Mar 20 | 0 | 28 | 6 | 1 |
| 31 Dec 19 | 0 | -8 | 6 | 0 |
| 30 Sep 19 | 0 | -5 | 3 | 1 |
| 30 Jun 19 | 0 | -42 | 3 | 4 |
Quality Earnings: 2O9 is currently unprofitable.
Growing Profit Margin: 2O9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2O9 is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare 2O9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2O9 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.6%).
Return on Equity
High ROE: 2O9's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.